SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: biofisher who wrote (4587)8/4/2010 3:32:39 PM
From: tom pope  Respond to of 4676
 
The dropouts were due to unexplained - so far as I could tell - "adverse events." Were they enzyme related?
A %age of the placebo group also dropped out due to adverse events. Again unspecified.



To: biofisher who wrote (4587)8/4/2010 3:53:51 PM
From: tuck  Read Replies (1) | Respond to of 4676
 
For the general population of hypercholesterolemia patients on statins, incidence of persistent ALT/AST 3x ULN is much lower, like 1%. In HFH patients on statins, about twice that, probably because they take a higher dose than most hypercholesterolemia patients and there's a dose dependent effect on liver enzymes.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News